(VIANEWS) - New Residential Investment (NRZ), AZZ Incorporated (AZZ), Exelixis (EXEL) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. New Residential Investment (NRZ)
31.5% sales growth and 13.32% return on equity
For the 12 trailing months, the company's return-on-equity, which is a measure of the business' profitability relative to shareholders' equity, was 13.32%.Revenue Growth
Year-on-year quarterly revenue growth grew by 153.8%, now sitting on 3.01B for the twelve trailing months.
Dividend Yield
According to Morningstar, Inc., there will be a next dividend payment on March 31, 2022. The forward-annual dividend rate for 2020 is estimated at 1 while the forward-annual dividend yield is estimated at 9.21%.
2. AZZ Incorporated (AZZ)
21.8% sales growth and 13.17% return on equity
AZZ Inc. provides galvanizing and metal coating solutions, welding solutions, specialty electrical equipment, and engineered services to the power generation, transmission, distribution, refining, and industrial markets in the United States and internationally. The company operates through two segments, Infrastructure Solutions and Metal Coatings. The Metal Coatings segment offers hot dip galvanizing, powder coating, anodizing, plating, and other metal coating applications to the steel fabrication and other industries. It serves fabricators or manufacturers that provide services to the electrical and telecommunications, bridge and highway, petrochemical, and general industrial markets, as well as original equipment manufacturers. The Infrastructure Solutions segment provides products and services to support industrial and electrical applications. It offers custom switchgear, electrical enclosures, medium and high voltage bus ducts, explosion proof and hazardous duty lighting, nuclear safety-related equipment, and tubular products, as well as solutions and engineering resources to multi-national companies and small independent companies. This segment sells its products through internal sales force, manufacturers' representatives, distributors, and agents. The company was incorporated in 1956 and is headquartered in Fort Worth, Texas.
Earnings Per Share
As for profitability, AZZ Incorporated has a trailing twelve months EPS of $3.89.
PE Ratio
AZZ Incorporated has a trailing twelve months price to earnings ratio of 11.43. Meaning, the purchaser of the share is investing $11.43 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.17%.Sales Growth
AZZ Incorporated's sales growth is 56.7% for the current quarter and 21.8% for the next.
Volume
Today's AZZ Incorporated volume is 137290, which is 5.65% less than its 145518 average volume.
Moving Average
AZZ Inc.'s value is greater than its $50.57 moving average and higher than its $200 moving average $42.11.3. Exelixis (EXEL)
20% sales growth and 13.36% return on equity
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of patients with progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. In addition, it is developing XL092, an oral tyrosine kinase inhibitor that targets VEGF receptors, MET, AXL, MER, and other kinases implicated in growth and spread of cancer; XB002, an antibody-drug conjugate composed of human mAb against tissue factor (TF) for the treatment of advanced solid tumors; XL102, an orally bioavailable cyclin-dependent kinase 7 (CDK7) inhibitor for the treatment of advanced or metastatic solid tumors; and XB002 for the treatment of non-hodgkin's lymphoma. Exelixis, Inc. has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.
Earnings Per Share
As for profitability, Exelixis has a trailing twelve months EPS of $0.97.
PE Ratio
Exelixis has a trailing twelve months price to earnings ratio of 16.54. Meaning, the purchaser of the share is investing $16.54 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 13.36%.Yearly Top and Bottom Value
Exelixis's stock is valued at $16.04 at 05:22 EST, way under its 52-week high of $23.40 and above its 52-week low of $14.87.
Revenue growth
The year-on-year revenue growth was 25.4%. It now stands at 1.64B in the 12 trailing months.
4. Qualys (QLYS)
17.5% sales growth and 26.77% return on equity
Qualys, Inc. offers cloud-based IT, security, compliance and other services in the United States as well as internationally. Qualys Cloud apps are offered by the company. They include Vulnerability management; Vulnerability Detection, Response; Threat protection; Continuous monitoring; Patch Management. The company's Qualys Cloud Platform offers integrated IT and security solutions that enable customers to manage IT assets and identify vulnerabilities. Asset tagging, dashboards, collaboration and questionnaires are all provided by the company. It offers solutions via its sales team, its channel partners (security consulting organisations, managed service providers and resellers) as well as its own network. The company serves small and medium-sized enterprises as well as government agencies. It was founded in 1999, and has its headquarters in Foster City in California.
Earnings per Share
Qualys' trailing 12 month EPS is $2.64.
PE Ratio
Qualys' trailing 12-month price-earnings ratio is 42.24. The purchaser of the shares is therefore investing $42.24 per dollar in annual earnings.
For the 12 trailing months, the company's return-on-equity, which is a measure of the profitability of a company relative to shareholders' equity, was 26.77%.Sales Growth
Qualys saw a 17.5% increase in sales for its current quarter, and 18.6% in the following.
Annual Top and Bottom Value
Qualys' stock was valued at $111.51 at 5:22 EST at the time of writing. This is way lower than its 52 week high of $162.36, and much higher than its 52 week low of $107.69.
5. First BanCorp. New (FBP)
15% sales growth and 17.64% return on equity
First BanCorp. operates as the bank holding company for FirstBank Puerto Rico that provides a range of financial products and services to retail, commercial, and institutional clients. The company operates in six segments: Commercial and Corporate Banking, Mortgage Banking, Consumer (Retail) Banking, Treasury and Investments, United States Operations, and Virgin Islands Operations. The Commercial and Corporate Banking segment offers commercial real estate and construction loans, floor plan financing, and cash and business management services. The Mortgage Banking segment is involved in the origination, sale, and servicing of various residential mortgage loan products and related hedging activities; and acquisition and sale of mortgages in the secondary markets. The Consumer (Retail) Banking segment provides auto, boat, and personal loans; credit cards; lines of credit; deposit products comprising interest bearing and non-interest bearing checking and savings accounts, individual retirement accounts, and retail certificates of deposit (CDs); finance leasing and insurance services. The Treasury and Investments segment engages in the treasury and investment management activities, such as funding and liquidity management. The United States Operations segment offers checking, savings, and money market accounts, as well as retail CDs; and residential mortgages, home equity loans, lines of credit, and term loans, as well as Internet banking, cash management, remote data capture, automated clearing house transaction services. The Virgin Islands Operations segment is involved in the consumer, commercial lending, and deposit-taking activities. As of December 31, 2019, the company operated 46 branches in Puerto Rico, 11 branches in the U.S. Virgin Islands and British Virgin Islands, and 10 branches in the state of Florida. First BanCorp. was founded in 1948 and is headquartered in Santurce, Puerto Rico.
Earnings Per Share
As for profitability, First BanCorp. New has a trailing twelve months EPS of $0.73.
PE Ratio
First BanCorp. New has a trailing twelve months price to earnings ratio of 17.56. Meaning, the purchaser of the share is investing $17.56 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 17.64%.6. Balchem Corporation (BCPC)
7.2% sales growth and 12.2% return on equity
Balchem Corporation designs, produces, markets and distributes specialty performance ingredients for industrial and commercial markets, both in the United States as well as internationally. The company operates in three main segments, Human Nutrition & Health and Animal Nutrition & Health. Specialty Products is also part of its business. Human Nutrition & Health supplies ingredients for the food- and beverage industries. Products include extrusion, agglomeration and blended lipid systems. They also offer liquid flavor delivery systems and juice and dairy bases. The segment offers microencapsulation for various purposes; human-grade choline nutrients, and mineral amino acid and chelated products to support nutrition and health. Animal Nutrition & Health offers microencapsulated products for enhancing health and milk production. It also provides nutrient supplements for ruminant livestock. Specialty Products offers ethylene dioxide primarily for the healthcare industry. Single-use canisters with Ethylene oxide are also available for sterilizing re-usable items. The segment markets and sells propylene dioxide, which is a fumigant that aids in controlling insects and microbiological spoilage. It also sterilizes re-usable devices by sterilizing single use canisters with ethylene oxide. It sells products via sales representatives, independent distributors and agents. Balchem Corporation was founded in 1967. It is located in New Hampton in New York.
Earnings Per Share
As for profitability, Balchem Corporation has a trailing twelve months EPS of $3.35.
PE Ratio
Balchem Corporation has a trailing twelve months price to earnings ratio of 36.45. Meaning, the purchaser of the share is investing $36.45 for every dollar of annual earnings.
The company's return on equity, which measures the profitability of a business relative to shareholder's equity, for the twelve trailing months is 12.2%.Dividend Yield
According to Morningstar, Inc., Dec 22nd 2022 will be the next distribution. The forward dividend rate and yield are 0.71 and 0.58% respectively.